Lake Bleu Capital is a Hong Kong-based venture capital firm that focuses on mid-to-late-stage healthcare investments across Asia, with a particular emphasis on Greater China. The firm employs a value-creating strategy, identifying high-growth potential companies through rigorous bottom-up fundamental research and offering strategic guidance and value-added services.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is growth (50% of deals). Average disclosed round size is $230.8M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Growth
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Insilico Medicine | Series C | $255M | Jun 2021 |
 I-Mab | Growth | $418M | Sep 2020 |
 RemeGen | Growth | $100M | Apr 2020 |
| AAkeso, Inc. | Series D | $150M | Nov 2019 |
Top Co-Investors
OrbiMed4 shared
Lilly Asia Ventures2 shared
Loyal Valley Capital2 shared
Vivo Capital1 shared
Janchor Partners1 shared
Hudson Bay Capital1 shared
Hillhouse Capital1 shared
GIC1 shared
Avidity Partners1 shared
Invus1 shared
Perceptive Advisors1 shared
Cormorant Asset Management1 shared
Sequoia Capital1 shared
Warburg Pincus1 shared
Pavilion Capital1 shared
Eight Roads Ventures1 shared
Sinovation1 shared
Bold Capital Partners1 shared
Baidu Venture1 shared
CPE1 shared
Last updated: 16 April 2026